Stockreport

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

Kezar Life Sciences, Inc.  (KZR) 
Last kezar life sciences, inc. earnings: 8/7 04:05 pm Check Earnings Report
PDF PORTOLA Phase 2a clinical trial in patients with autoimmune hepatitis (AIH) to continue without modification following review by Independent Data Monitoring Committee (I [Read more]